AC Immune amends Lilly collaboration, plans tau drug studies

AC Immune amended its 2018 collaboration with Eli Lilly, receiving a CHF10 million upfront payment and remaining eligible for development, regulatory and commercial milestones in excess of CHF1.7 billion plus low-double-digit tiered royalties; the company expects to start IND-enabling studies in H1 2026 and an additional milestone upon Phase 1 dosing. The firm reported supportive preclinical Morphomer data, Phase 1 PET tracer imaging for TDP-43, and launched a Phase 1 trial for ACI-19764 (NLRP3 inhibitor); Jefferies reiterated a Buy with a $7 target. Market metrics: market cap ~$268M, stock up ~70% over the past year, and analysts forecast revenue growth of ~177% in fiscal 2026 — effects are company-specific and likely to move the stock rather than broader markets.

Analysis

The partnership signal functions less as incremental revenue and more as a validation vector that compresses M&A and option-value timing for small-cap neuro developers. When a well-capitalized pharma exhibits programmatic interest it shifts market expectations from pure clinical binary outcomes toward strategic exercisability — meaning buyout probabilities rise and the path to a liquidity event shortens, compressing the time premium investors should demand.

Diagnostics progress (imaging tracer de-risking) is a separate, under-appreciated value driver: a validated tracer increases addressable market for therapeutics by shortening trials and enabling target-enriched cohorts, which mechanically lowers trial cost and timeline by an estimated 20–40% in CNS studies. That positive externality benefits any company that can pair a therapeutic candidate with a reliable biomarker, shifting competition from solely therapeutic efficacy to companion-diagnostic control.

Tail risks remain classic for CNS small caps — nonlinearity in clinical translation, rapid cash burn, and dilution from follow-on financing. Near-term catalysts are binary and clustered on a 12–24 month horizon; that clustering amplifies both implied volatility and takeover optionality, creating an asymmetric payoff that is real but concentrated in time. Liquidity and IV levels will therefore be as important as directional conviction when sizing positions.

Key Decisions for Investors

• Buy ACIU equity sized 1–2% of NAV as a thematic, event-driven stake; horizon 12–18 months. Rationale: capture strategic optionality from pharma validation while keeping exposure limited to binary clinical/opt-in outcomes. Risk management: hard stop at -40% from entry or trim to half-sized position on +50% rally.
• Purchase a 12–18 month call spread on ACIU to cap premium outlay and target 2–4x payoff if catalysts land (buy nearer-term ITM/ATM call, sell higher-strike call to fund). Enter when implied vol rank is below the 80th percentile for the name; maximum loss = net debit, upside = strike spread minus debit.
• Pair trade to isolate idiosyncratic upside: long ACIU (0.5–1% NAV) / short equal-dollar XBI (or small-cap biotech basket) to neutralize sector beta; horizon 6–12 months. This reduces exposure to sector-wide risk such as financing windows while keeping upside if ACIU-specific scientific/strategic events occur.
• If headline-driven spike (>50% intraday) occurs, sell into strength: take 30–50% profits on the equity leg and retain a defensive options position (long-dated OTM calls) to preserve upside while removing momentum-driven exposure. This captures re-rating while protecting against short-term mean reversion.